Clinical Trials for Other Solid Tumor

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates the efficacy of combining fianlimab, a LAG-3 blocking antibody, with cemiplimab (an anti-PD-1 antibody) and chemotherapy, against cemiplimab and chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) at stages IIIB, IIIC, or IV who have not yet received systemic treatment for recurrent or metastatic disease.

ClinicalTrials.gov ID: NCT05800015

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the efficacy of combining datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, with pembrolizumab, with or without platinum chemotherapy, in treatment-naïve adults with advanced or metastatic non-squamous NSCLC, PD-L1 TPS &lt;50%, and no actionable genomic alterations. It compares these combinations to the standard regimen of pembrolizumab with pemetrexed and platinum chemotherapy.

ClinicalTrials.gov ID: NCT05555732

Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors (The HARMONIC Study)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial is for never smoker patients with relapsed advanced primary adenocarcinoma of the lung, featuring actionable genomic alterations, who have progressed after tyrosine kinase inhibitor therapies. It examines the combination of the investigational multi-tyrosine kinase receptor inhibitor LP-300 with carboplatin and pemetrexed, compared to the standard carboplatin-pemetrexed regimen.

ClinicalTrials.gov ID: NCT05456256

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors who have limited treatment options, evaluating the efficacy and safety of IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein targeting the PD-1/PD-L1 pathway and activating the IL-2 pathway to enhance tumor-specific T cell activity.

ClinicalTrials.gov ID: NCT06281678

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adults with locally advanced or metastatic EGFR-mutant non-squamous NSCLC who have not received prior systemic therapy, comparing osimertinib alone versus osimertinib combined with Datopotamab Deruxtecan, an investigational antibody-drug conjugate targeting TROP2.

ClinicalTrials.gov ID: NCT06350097

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with advanced or metastatic non-squamous NSCLC who have specific genetic mutations like EGFR and have received prior therapies, comparing the efficacy of sacituzumab tirumotecan, a TROP2-targeting antibody-drug conjugate, to standard chemotherapy agents docetaxel or pemetrexed.

ClinicalTrials.gov ID: NCT06074588

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial compares the efficacy and safety of rilvegostomig, a bispecific monoclonal antibody targeting PD-1 and TIGIT, against pembrolizumab, both combined with platinum-based chemotherapy, for first-line treatment in patients with metastatic non-squamous NSCLC expressing PD-L1. Participants must have stage IV disease without certain genetic mutations and no prior treatment with specific systemic therapies or untreated brain metastases.

ClinicalTrials.gov ID: NCT06627647

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial involves patients aged 18 or older with locally advanced or metastatic non-squamous NSCLC harboring HER2-activating mutations, who have not received prior systemic therapy for advanced disease. It compares BAY 2927088, an oral HER2-targeting tyrosine kinase inhibitor, with the standard care regimen of pembrolizumab and platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT06452277

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves HLA-A2 positive patients with metastatic NSCLC who exhibit secondary resistance to immune checkpoint inhibitors, excluding those with EGFR, ALK, or ROS1 alterations. It compares the efficacy and safety of OSE2101, a therapeutic cancer vaccine targeting 10 neoepitopes to enhance cytotoxic T-cell response, against standard docetaxel chemotherapy.

ClinicalTrials.gov ID: NCT06472245

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates the efficacy of volrustomig, a bispecific antibody targeting PD-1 and CTLA-4, combined with chemotherapy compared to pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic NSCLC lacking EGFR, ALK, and ROS1 mutations and having PD-L1 expression under 50%.

ClinicalTrials.gov ID: NCT05984277